



THE DEATH TOLL OF VIRAL RESPIRATORY DISEASES AROUND THE WORLD IN 2020 WAS OVER 4,000,000

Current solution - Vaccines



Each Virus require a **specific vaccine**



Creating vaccine is **Long and expensive** process
(Plotkin et al. 2017)



Random mutation **reduces vaccine effectiveness**
(Skowronski et al. 2016)



Immune deficiency and allergy **prevent part of the population from been vaccinated**

Viritis solution Advantages

- ✓ 01. A single product can treat a wide range of viruses by combining several "Warheads"
- ✓ 02. Minimal and effectively negligible side effects are expected (considering the alternatives)
- ✓ 03. Unaffected by virus mutation
- ✓ 04. Can be administered to currently sick patients

Viritis solution - Bio Convergence

Combining nano-biological vectors together with our unique hybrid molecule to create a "Weapon" that can destroy viruses on the cellular level


Our solution consists of 3 parts

The casing - A biological nanobot that enable our molecule to enter the target cell

The body - A hybrid molecule that after activation by interacting with a virus signal the cell own mechanism to destroy its target

The warhead - A smaller molecule that have strong affinity to a specific part in the target virus. Each virus has its matching "warhead"

Market size The annually costs of influenza in the US




Business model- Technology Platform

In addition to Viritis patented molecule main use as an antiviral drug it can serve as a powerful therapeutic tool for many other diseases and conditions including the many forms of cancer and autoimmune diseases.

Licensing - Providing our molecule to pharma\Bio tech companies

Contract research - Using our molecule to conduct R&D custom projects

Milestones 2020-2022



Amit Turman
CEO

B.Sc. Biotechnology, Entrepreneur, acceleration programs manager and business development specialist with more than six (6) years of experience as a CEO and founder at several startup companies.



Amit Philosoph
Chief scientist

Phd in molecular virology and Pathology at the Hebrew University of Jerusalem. Researcher of Genetic Diseases in the Molecular Metabolic Department, Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel



Aaron Wistouch
CFO

Finance expert at institutional and capital markets. As an entrepreneur he founded and led two (2) financial venture to successful capitations. Aaron worked for the chief controller at the Israeli ministry of economics.